<turbo-stream action="append" target="news"><template>  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-secondary bg-gray-200">
          Neutral
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/aktien/Hutchison-China-MediTech-Limited-Sponsored-ADR-US44842L1035">Hutchison China MediTech Limited Sponsored ADR</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">GlobeNewsWire</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">vor etwa einem Monat</div>
        <span class="me-2 new badge text-secondary bg-gray-200" data-bs-toggle="tooltip"
              data-bs-title="Automatisch aus dem Englischen übersetzt. Standardsprache in den Einstellungen ändern."
              title="Automatisch aus dem Englischen übersetzt. Standardsprache in den Einstellungen ändern.">EN</span>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.globenewswire.com/news-release/2026/08/17/3345800/0/en/hutchmed-announces-orpathys-plus-tagrisso-demonstrated-statistically-significant-and-clinically-meaningful-improvements-in-progression-free-and-overall-survival-in-met-driven-egfr-.html">HUTCHMED kündigt an, dass ORPATHYS® plus TAGRISSO® statistisch signifikante und klinisch bedeutsame Verbesserungen des progressionsfreien und des Gesamtüberlebens bei MET-getriebenem, EGFR-mutiertem Lungenkrebs nach Progression unter TAGRISSO® zeigte</a>
    </div>

      <div class="me-0 me-md-5">
        — Erste globale Phase‑III‑Studie, die in diesem Setting signifikante Vorteile beim progressionsfreien Überleben und beim Gesamtüberleben zeigt —
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/aktien/Hutchison-China-MediTech-Limited-Sponsored-ADR-US44842L1035">Hutchison China MediTech Limited Sponsored ADR</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 news-box__source-badge">
          <img class="news-box__source-logo" alt="aktien.guide" src="https://aktien.guide/assets/logos/aktien_guide-9da0dc14.svg" />
        </div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">vor etwa 2 Monaten</div>
    </div>

    <div class="mb-2">
      <a data-turbo-frame="_top" href="https://aktien.guide/aktien/Hutchison-China-MediTech-Limited-Sponsored-ADR-US44842L1035#earnings-events-section">Hutchison China MediTech Limited Sponsored ADR Q2 2026 Earnings Call Transkript verfügbar</a>
    </div>

      <a data-controller="earnings-news-cta" data-earnings-news-cta-event-id-value="4674644" data-action="click-&gt;earnings-news-cta#open" data-turbo-frame="_top" class="btn btn-outline-primary btn--small border-0 mt-0 px-2" href="https://aktien.guide/aktien/Hutchison-China-MediTech-Limited-Sponsored-ADR-US44842L1035?earnings_event_id=4674644">
        Zusammenfassung anzeigen
        <i class="fa fa-arrow-right fa-fw"></i>
</a>  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
      <a data-turbo-frame="_top" href="https://aktien.guide/aktien/Hutchison-China-MediTech-Limited-Sponsored-ADR-US44842L1035#earnings-events-section">
        <div class="news-box__logo-frame mb-3 mb-md-0">
          <img class="news-box__logo" alt="Hutchison China MediTech Limited Sponsored ADR" src="https://aktien.guide/rails/active_storage/blobs/proxy/eyJfcmFpbHMiOnsiZGF0YSI6MTc0OTMsInB1ciI6ImJsb2JfaWQifX0=--ad59368323185aef29c16a673c32357186ee1eed/Hutchison-China-MediTech-Limited-Sponsored-ADR-US44842L1035.png" />
          <span class="news-box__logo-label">Earnings Call Transkript</span>
        </div>
</a>  </div>
</div>

  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-secondary bg-gray-200">
          Neutral
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/aktien/Hutchison-China-MediTech-Limited-Sponsored-ADR-US44842L1035">Hutchison China MediTech Limited Sponsored ADR</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">GlobeNewsWire</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">vor 3 Monaten</div>
        <span class="me-2 new badge text-secondary bg-gray-200" data-bs-toggle="tooltip"
              data-bs-title="Automatisch aus dem Englischen übersetzt. Standardsprache in den Einstellungen ändern."
              title="Automatisch aus dem Englischen übersetzt. Standardsprache in den Einstellungen ändern.">EN</span>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.globenewswire.com/news-release/2026/07/02/3321131/0/en/HUTCHMED-Announces-NMPA-Approval-for-ORPATHYS-for-the-treatment-of-Gastric-Cancer-Patients-with-MET-Amplification.html">HUTCHMED kündigt NMPA-Zulassung für ORPATHYS® zur Behandlung von Magenkrebspatienten mit MET-Amplifikation an</a>
    </div>

      <div class="me-0 me-md-5">
        Erster selektiver MET-Inhibitor, der in China für Patienten mit MET-amplifiziertem fortgeschrittenem Magenkrebs oder Adenokarzinom des gastroösophagealen Übergangs zugelassen wurde Erster selektiver MET-Inhibitor, der in China für Patienten mit MET-amplifiziertem fortgeschrittenem Magenkrebs oder Adenokarzinom des gastroösophagealen Übergangs zugelassen wurde
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-secondary bg-gray-200">
          Neutral
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/aktien/Hutchison-China-MediTech-Limited-Sponsored-ADR-US44842L1035">Hutchison China MediTech Limited Sponsored ADR</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">Business Wire</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">vor 3 Monaten</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.businesswire.com/news/home/20260623406678/en/Syndio-Acquires-Embrace.ai/">Syndio Acquires Embrace.ai</a>
    </div>

      <div class="me-0 me-md-5">
        SEATTLE--(BUSINESS WIRE)--Syndio, the Decision Intelligence for Pay company, today announced the acquisition of Embrace.ai, an agentic AI company built to deploy AI-driven automation across business workflows. The full Embrace.ai team, led by founders and enterprise software veterans Derek Butts and Seth Halpern, will join Syndio&#39;s product and go-to-market organization. The acquisition bolsters...
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-secondary bg-gray-200">
          Neutral
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/aktien/Hutchison-China-MediTech-Limited-Sponsored-ADR-US44842L1035">Hutchison China MediTech Limited Sponsored ADR</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">PRNewsWire</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">vor 3 Monaten</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.prnewswire.com/news-releases/edgewise-therapeutics-announces-positive-top-line-data-from-12-week-phase-2-cirrus-hcm-trial-with-edg-7500-in-obstructive-and-nonobstructive-hypertrophic-cardiomyopathy-hcm-302801108.html">Edgewise Therapeutics Announces Positive Top-Line Data from 12-Week Phase 2 CIRRUS-HCM Trial with EDG-7500 in Obstructive and Nonobstructive Hypertrophic Cardiomyopathy (HCM)</a>
    </div>

      <div class="me-0 me-md-5">
        – No relationship observed between EDG-7500 exposure and LVEF; no LVEF reductions below 50% – – Consistent and clinically meaningful improvements observed in echocardiogram parameters, biomarkers, symptoms and functional status across obstructive and nonobstructive HCM  – – EDG-7500 administration continued to be generally well tolerated – – Company to host webcast today at 8:30 a.m. Eastern Ti...
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-secondary bg-gray-200">
          Neutral
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/aktien/Hutchison-China-MediTech-Limited-Sponsored-ADR-US44842L1035">Hutchison China MediTech Limited Sponsored ADR</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">GlobeNewsWire</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">vor 3 Monaten</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.globenewswire.com/news-release/2026/06/16/3312225/0/en/isolved-Honors-Top-Performing-Partners-at-Annual-Connect-for-Partners-Event.html">isolved Honors Top-Performing Partners at Annual Connect for Partners Event</a>
    </div>

      <div class="me-0 me-md-5">
        LAS VEGAS, June 15, 2026 (GLOBE NEWSWIRE) -- Connect for Partners – isolved®, a provider of human capital management (HCM) solutions that help organizations recruit, retain and elevate their workforce, proudly recognized top-performing partners during its annual isolved Connect for Partners. Now in its ninth year, Connect for Partners has grown into the premier gathering for the isolved partner...
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-secondary bg-gray-200">
          Neutral
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/aktien/Hutchison-China-MediTech-Limited-Sponsored-ADR-US44842L1035">Hutchison China MediTech Limited Sponsored ADR</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">GlobeNewsWire</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">vor 3 Monaten</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.globenewswire.com/news-release/2026/06/15/3311996/0/en/isolved-Introduces-New-Strategic-Marketplace-Partners-at-Connect-2026-Extending-People-Cloud-Capabilities-for-Employers-and-Employees.html">isolved Introduces New Strategic Marketplace Partners at Connect 2026, Extending People Cloud™ Capabilities for Employers and Employees</a>
    </div>

      <div class="me-0 me-md-5">
        LAS VEGAS, June 15, 2026 (GLOBE NEWSWIRE) -- Connect For Partners – isolved, a provider of human capital management (HCM) solutions that help organizations recruit, retain and elevate their workforce, today announced new additions to its Strategic Marketplace — a curated ecosystem of best-in-class technology partners, each selected for the specific, meaningful value they bring to isolved client...
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-secondary bg-gray-200">
          Neutral
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/aktien/Hutchison-China-MediTech-Limited-Sponsored-ADR-US44842L1035">Hutchison China MediTech Limited Sponsored ADR</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">GlobeNewsWire</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">vor 3 Monaten</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.globenewswire.com/news-release/2026/06/15/3311865/0/en/paychex-recognized-as-a-top-worktech-company-by-time.html">Paychex Recognized as a Top WorkTech Company by TIME</a>
    </div>

      <div class="me-0 me-md-5">
        Paychex named a leading HCM provider to TIME&#39;s America&#39;s Top WorkTech Companies 2026 List List identifies the most impactful and financially strong companies that have established themselves as leaders in shaping how people and organizations work ROCHESTER, N.Y., June 15, 2026 (GLOBE NEWSWIRE) -- Paychex, Inc. (Nasdaq: PAYX), an industry-leading human capital management (HCM) company, today ann...
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

</template></turbo-stream><turbo-stream action="replace" target="link"><template><div id="link">
    <a class="btn btn-outline-primary btn--small" data-turbo-stream="" href="/news/Hutchison-China-MediTech-Limited-Sponsored-ADR-US44842L1035/load_more?page=3">
      Mehr Neuigkeiten anzeigen
      <i class="fa fa-arrow-down fa-fw"></i>
</a></div>
</template></turbo-stream>